Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
Advanced Hormone Sensitive Prostate Cancer
Conditions: official terms
Prostatic Neoplasms
Study Type
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Name: degarelix
Type: Drug
Overall Status
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Male
Criteria: Inclusion Criteria:

- Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion Criteria:

- Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded

- Planned intermittent or short-term (< 12 months) degarelix treatment

- Planned addition of, or switch to another form of androgen deprivation therapy during the study
Groene Hart Ziekenhuis (there may be other sites in this country)
Gouda, Netherlands
Status: Recruiting
Start Date
September 2014
Completion Date
September 2016
Ferring Pharmaceuticals
Ferring Pharmaceuticals
Record processing date processed this data on July 28, 2015 page